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Introduction {#acn3511-sec-0001}
============

Xeroderma pigmentosum (XP) is a rare autosomal recessive disorder, caused by mutations in the nucleotide excision repair (NER) pathway genes.[1](#acn3511-bib-0001){ref-type="ref"}, [2](#acn3511-bib-0002){ref-type="ref"}, [3](#acn3511-bib-0003){ref-type="ref"}, [4](#acn3511-bib-0004){ref-type="ref"}, [5](#acn3511-bib-0005){ref-type="ref"} This system repairs the DNA structure after distortion caused by ultraviolet‐induced photoproducts.[3](#acn3511-bib-0003){ref-type="ref"} Depending on the affected gene, groups from XP‐A to XP‐G and XP‐V have been described.[5](#acn3511-bib-0005){ref-type="ref"}

Most XP patients present with cutaneous, ocular, and neurological features.[4](#acn3511-bib-0004){ref-type="ref"}, [5](#acn3511-bib-0005){ref-type="ref"}, [6](#acn3511-bib-0006){ref-type="ref"}, [7](#acn3511-bib-0007){ref-type="ref"}, [8](#acn3511-bib-0008){ref-type="ref"} Some groups[9](#acn3511-bib-0009){ref-type="ref"} exhibit extreme sun sensitivity since infancy, resulting in severe sunburn to minimal sun exposure.[4](#acn3511-bib-0004){ref-type="ref"} Lentigines in sun‐exposed areas and multiple cutaneous tumors are also distinctive for the disease. Secondly, ocular surface pathology, eyelid damage, and ophthalmic neoplasms are also common. Neurological manifestations occur in 20--30% of cases,[4](#acn3511-bib-0004){ref-type="ref"} usually after the cutaneous signs. Cognitive impairment, cerebellar signs, sensorineural hearing loss, and sensorimotor axonal neuropathy have been reported.[6](#acn3511-bib-0006){ref-type="ref"}, [9](#acn3511-bib-0009){ref-type="ref"} In advanced cases, movement disorders may appear.[7](#acn3511-bib-0007){ref-type="ref"}, [8](#acn3511-bib-0008){ref-type="ref"}, [10](#acn3511-bib-0010){ref-type="ref"}

There is noteworthy phenotypic variability among the different XP groups and within each group.[5](#acn3511-bib-0005){ref-type="ref"}, [7](#acn3511-bib-0007){ref-type="ref"} Thus, XP can be misdiagnosed in the absence of early dermatological features, especially in late‐onset neurodegenerative phenotypes. To our knowledge, we describe here the first XP‐G and XP‐B families whose main neurological features tightly resemble a Huntington\'s disease‐like (HD‐like) phenotype.

Patients and Methods {#acn3511-sec-0002}
====================

Informed consent was obtained from both patients. This study was performed in accordance with protocols approved by the Research Ethics Committee of Guy\'s and St Thomas' Foundation Trust (12/LO/0325). The diagnostic techniques have been previously described.[5](#acn3511-bib-0005){ref-type="ref"}, [11](#acn3511-bib-0011){ref-type="ref"} Pedigrees were designed using the CeGaT Pedigree Chart Designer tool^®.^

Results {#acn3511-sec-0003}
=======

Case 1 {#acn3511-sec-0004}
------

The first case was a 63‐year‐old lady who had suffered from sun sensitivity since childhood, with two episodes of severe sunburn. She had not received any prior neuropsychiatric treatments, including dopamine blocking or depleting agents. First neurological symptoms appeared when she was 53, as mild short‐term memory impairment, and loss of her standards of personal hygiene. Two years later, she complained of hearing loss and some hyperkinetic movements were noted. During the ensuing 5 years, she experienced progressive deterioration in neuropsychiatric symptoms with disinhibition, apathy and neglect of personal hygiene; as well as worsening of balance and involuntary movements, resulting in multiple falls. Subsequently, she was referred to a movement disorder specialist, who found she had generalized chorea and commenced a treatment with 7.5 mg olanzapine, with improvement of the hyperkinetic movements.

When assessed in our clinic, she was found to have extensive lentigines and hypopigmented macules at sun‐exposed sites. She had photophobia, lagophthalmos, mild keratopathy and sunken eyes. Neurologically, she was disoriented and had poor executive function. She had a full range of external ocular movements, with nystagmus, slow initiation of saccades, and sluggish pupils. She showed pyramidal features in the lower limbs (weakness, hyperreflexia and Babinski\'s sign) and cerebellar signs in the upper limbs (dysmetria and intentional tremor). The gait was broad‐based with mild camptocormia and preserved arm swing. There was chorea in the fingers, as well as, neck and trunk dystonia. Her clinical status progressively declined with hallucinations, delusions, disrupted behavior and loss of independent gait (Video [S1](#acn3511-sup-0001){ref-type="supplementary-material"}). She died at the age of 69, following a pulmonary thromboembolism.

Her parents came from the same village in Cyprus. The patient was the third of seven siblings. Two siblings presented sun sensitivity, lentigines, and developed cognitive impairment and slurred speech in their 50s. They died at the age of 62 and 59. The fourth sibling was a lady who showed pigmentary changes and lentigines, as well as slurred speech and cerebellar ataxia from her 50s. Later, she developed chorea and dementia. All the three affected siblings developed hearing impairment. The other siblings and the patient\'s daughters were unaffected (Fig. [1](#acn3511-fig-0001){ref-type="fig"}A).

![**A:** case 1 pedigree (member order, age, phenotype/comments). The subjects with a dot are carriers for the mutation. **B**: case 2 pedigree (member order, age, phenotype/comments). The pedigree was altered to preserve anonymity.](ACN3-5-102-g001){#acn3511-fig-0001}

Her brain MRI (Fig. [2](#acn3511-fig-0002){ref-type="fig"}) showed nonspecific atrophy of the brain and cerebellum without involvement of the caudate nuclei. Nerve conduction studies were normal. Pure tone audiometry revealed bilateral sensorineural hearing loss. Three blood films for acanthocytes were negative, as well as lupus anticoagulant and anticardiolipin antibodies. An extensive battery of genetic tests yielded negative results, including: HD; familial prion disease (*PRNP*); HDL‐2 (junctophilin‐3); *C9orf72* expansion; dentatorubral‐pallidoluysian atrophy (DRPLA, atrophin‐1); spinocerebellar ataxias (SCA) 1, 2, 3, 6, 7, 12, and 17. Owing to the significant cutaneous involvement, the suspicion of XP was raised and an unscheduled DNA synthesis assay was performed. Her skin fibroblasts were defective for the NER system, showing less than 15% of repair activity after ultraviolet radiation. XP genes sequencing showed a homozygous single nucleotide substitution (c.869T\>A) in exon 7 of the *XP‐G/ERCC5* gene. This is predicted to cause a single amino acid substitution (p.Ile290Asn) and has been previously reported as a pathogenic missense mutation.[5](#acn3511-bib-0005){ref-type="ref"} The patient was therefore diagnosed with late‐onset XP‐G. Her affected sister was homozygous for the same mutation. Two of the unaffected siblings were carriers.

![T2‐weighted image MRI from case 1.](ACN3-5-102-g002){#acn3511-fig-0002}

Case 2 {#acn3511-sec-0005}
------

The second case was a 52‐year‐old patient who was easily sunburned since childhood, and had lentigines since the age of 2 years. Regarding previous pharmacological treatments, no prior dopamine antagonists were noted. A melanoma in the right corneal limbus was detected at the age of 22 and the first of multiple nonmelanoma cancers was diagnosed 7 years later. Due to a recurrence of the melanoma, an enucleation of the eye was performed at the age of 36 years old. Neurologically, the patient presented at the age of 17 with severe bilateral sensorineural hearing loss. On examination, the patient had dense lentigines and hypopigmented macules on sun‐exposed sites such as the face, neck and arms. There were also numerous cherry angiomata at those sites. Choreic movements, with grimaces and emotional lability were noted. Despite normal tone and power throughout, pyramidal signs were found (brisk reflexes and bilateral Babinski\'s sign). The upper limbs showed dysmetria and intentional tremor. There was also some numbness in the right foot and a broad‐based gait. One year later, the patient complained of neck pain spreading to the left arm. After several investigations, she was diagnosed with a left upper lobe lung neoplasm. The patient died at the age of 55, due to complications of metastatic lung cancer.

One of the patient\'s siblings also had multiple skin tumors, early deafness and required enucleation of one eye due to melanoma (Fig. [1](#acn3511-fig-0001){ref-type="fig"}B).

The patient\'s MRI showed diffuse cerebral and cerebellar atrophy. Genetic analysis revealed heterozygous mutations in the *XP‐B/ERCC3* gene (namely, c.296T\>C, resulting in the missense mutation p.Phe99Ser; and c.1273C\>T, producing the nonsense mutation p.Arg425X), both of which have been previously reported.[5](#acn3511-bib-0005){ref-type="ref"}, [11](#acn3511-bib-0011){ref-type="ref"} Therefore, the diagnosis of XP‐B was made at the age of 43. The affected sibling shared the same genotype.

Discussion {#acn3511-sec-0006}
==========

Both index cases exemplify the challenge of XP diagnosis in late‐onset neurodegenerative phenotypes, especially in the presence of inconspicuous skin manifestations.

Neurological symptoms in XP patients can constitute a major source of disability and can carry higher rates of mortality in patients, compared to those without neurological involvement (37% vs. 29%).[12](#acn3511-bib-0012){ref-type="ref"} While strict photoprotection can prevent cutaneous and ophthalmological complications, there are no treatments to slow down the progression of the neurological disease. Neurologists should proactively investigate the presence of lentigines in sun‐exposed areas (face, neck, hands...), a previous history of easy or severe sunburn, or previous skin cancers, even if the first cutaneous signs occurred in childhood.

Both cases fulfilled the criteria for HD‐like syndromes[13](#acn3511-bib-0013){ref-type="ref"}: presence of movement disorders consistent with HD, a negative genetic test for HD, the occurrence of cognitive impairment and/or behavioral disturbances, and a positive family history for analogous neurological disorders. HD‐like syndromes are challenging entities, since a definite genetic diagnosis is reached in less than 3% of cases.[14](#acn3511-bib-0014){ref-type="ref"} Previously, the principal identified diseases were *C9orf72* expansion, SCA 17, HDL‐1 (mutations in *PRNP*) and HDL‐2 (mutations in junctophilin‐3). Conditions such as DRPLA, neuroferritinopathy or chorea‐acanthocytosis can also present as HD‐like disorders. The main characteristics of these conditions are summarized in Table [1](#acn3511-tbl-0001){ref-type="table-wrap"}.[11](#acn3511-bib-0011){ref-type="ref"}, [13](#acn3511-bib-0013){ref-type="ref"}, [14](#acn3511-bib-0014){ref-type="ref"}, [15](#acn3511-bib-0015){ref-type="ref"}, [16](#acn3511-bib-0016){ref-type="ref"}, [17](#acn3511-bib-0017){ref-type="ref"}, [18](#acn3511-bib-0018){ref-type="ref"}, [19](#acn3511-bib-0019){ref-type="ref"}, [20](#acn3511-bib-0020){ref-type="ref"}

###### 

Features of the main HD‐like syndromes compared to XP cases.[11](#acn3511-bib-0011){ref-type="ref"}, [13](#acn3511-bib-0013){ref-type="ref"}, [14](#acn3511-bib-0014){ref-type="ref"}, [15](#acn3511-bib-0015){ref-type="ref"}, [16](#acn3511-bib-0016){ref-type="ref"}, [17](#acn3511-bib-0017){ref-type="ref"}, [18](#acn3511-bib-0018){ref-type="ref"}, [19](#acn3511-bib-0019){ref-type="ref"}, [20](#acn3511-bib-0020){ref-type="ref"}

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                          Spinocerebellar ataxia type‐17                   Huntington disease‐like 1                Huntington disease‐like 2                     DRPLA                                                   Neuroferritinopathy                            Chorea‐Acanthocytosis                   XP‐F                                            XP‐G                              XP‐B
  ----------------------- ------------------------------------------------ ---------------------------------------- --------------------------------------------- ------------------------------------------------------- ---------------------------------------------- --------------------------------------- ----------------------------------------------- --------------------------------- ----------------------------------------------------------
  Inheritance             AD                                               AD                                       AD                                            AD                                                      AD                                             AR                                      AR                                              AR                                AR

  Gene                    *TBP*                                            *PRNP*                                   *JPH3*                                        *ATN1*                                                  *FTL*                                          *VPS13A*                                *ERCC4*                                         *ERCC5*                           *ERCC3*

  Mutation                Expanded CAG/CAA                                 Octapeptide repeat insertion             Expanded GTC/CAG                              Expanded CAG                                            Adenine insertion in exon 4                    Various                                 Various (p.Arg799Trp)                           p.Ile290Asn                       p.Phe99Ser, p.Arg425X

  Ethnicity               Caucasian, Asian                                 France, Netherlands                      Black South African                           Japan                                                   France                                         Japan, French‐Canadian                  Caucasian, Japan                                Greek Cypriot                     Caucasian/Caribbean

  Onset                   3--75 y.o.                                       20--45 y.o.                              20--40 y.o.                                   20--30 y.o.                                             40 y.o.                                        20--30 y.o.                             30--47 y.o.                                     45 y.o.                           Early childhood

  Survival                N/R                                              1--10 y.                                 10--20 y.                                     10--15 y.                                               N/R                                            15--20 y.                               \>20 y.                                         \>20 y.                           \>50 y.

  Movement disorders      Chorea (20%)                                     Chorea, rigidity                         Dystonia \> Chorea                            Chorea                                                  Chorea, dystonia, PD‐like                      Chorea, dystonia, tics                  Chorea                                          Chorea                            Chorea

  Cerebellar signs        ++ (\>90%)                                       \+                                       ‐                                             ++                                                      ‐                                              ‐                                       ++                                              ++                                ++

  Cognitive involvement   ++ (100%)                                        ++                                       ++ (100%)                                     ++                                                      ++                                             ++                                      \+                                              ++                                \+

  Psychiatric symptoms    ‐                                                ++                                       ++ (100%)                                     ++                                                      ‐                                              ++                                      ‐                                               ++                                ‐

  Seizures                \+ (50%)                                         \+                                       ‐                                             \+ (young onset)                                        ‐                                              \+ (50%)                                ‐                                               ‐                                 ‐

  Other features                                                                                                    No peripheral nerve or muscle abnormality     Myoclonus (young onset)                                 Action‐specific orofacial dystonia             Tongue protrusion and biting.\          Mild sun sensitivity, freckles. Skin tumors.    Sun sensitivity, freckles.\       SN hearing loss.\
                                                                                                                                                                                                                                                                         Neuropathy.\                                                                            Ocular disease.\                  Sun sensitivity, freckles, skin tumors. Ocular melanoma.
                                                                                                                                                                                                                                                                         Amyotrophy.                                                                             SN hearing loss.                  

  MRI                     Cerebellar atrophy. Rim enhancement of putamen   Mild cortical and subcortical atrophy.   Atrophy of caudate and cerebral hemispheres   T2WI‐hyperintense white matter lesions and PC atrophy   T2\*WI‐hypointense signal in BG and thalamus   Striatal atrophy, maximum in caudate.   Cerebellar, cortical and subcortical atrophy.   Cortical and cerebellar atrophy   Cortical and cerebellar atrophy.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD, autosomal dominant; AR, autosomal recessive; *TBP*, TATA‐box binding protein; *PRNP*, prion protein (PrP); *JPH3*, junctophilin‐3; *ATN1*, atrophin‐1; *FTL*, ferritin light chain; *VPS13A*, chorein; *ERCC4*, excision repair cross‐complementing protein‐4; *ERCC5*, excision repair cross‐complementing protein‐5; *ERCC3*, excision repair cross‐complementing protein‐3; y.o., years old; y., years; N/R, not reported; PD‐like, Parkinson\'s disease‐like; ‐, not prominent; +, common; ++, very frequent; SN, sensorineural; T2WI, T2‐weighted image MRI, PC, pontocerebellar; T2\*WI, T2\*(Echo gradient)‐weighted image MRI; BG: Basal Ganglia.
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We have presented here the occurrence of chorea and cognitive impairment in patients with mutations in different genes of the NER pathway (*ERCC5* and *ERCC3*). In a recent report by Carré et al.,[15](#acn3511-bib-0015){ref-type="ref"} two XP‐F patients (with mutations in the *ERCC4* gene) with chorea and cerebellar ataxia were also described. Consequently, we reinforce the notion that XP should be included in the differential diagnosis of HD‐like syndromes. The suspicion of XP should be raised if there is a history of skin disorder, even as mild as in the first presented case, and alternative genetic testing is negative.

The cases in this report illustrate novel pathophysiological mechanisms. Since a DNA repair disorder can mimic HD, the NER pathway might be of importance for both conditions. Apart from its role against photoproducts, the NER system also repairs the damage caused by inner sources, such as oxidative damage.[3](#acn3511-bib-0003){ref-type="ref"} Due to the NER system impairment, both nuclear and mitochondrial DNA (mtDNA) can accumulate mutations. It is known that mtDNA damage and mitochondrial dysfunction occur in HD.[2](#acn3511-bib-0002){ref-type="ref"} Therefore, NER disruption might contribute to the mitochondrial damage and neuronal loss in HD. Moreover, XP‐B and XP‐G are components of the transcription factor IIH (TFIIH),[21](#acn3511-bib-0021){ref-type="ref"}, [22](#acn3511-bib-0022){ref-type="ref"} which participates in transcription processes. Dysregulation of this mechanism might contribute to the neurodegeneration in XP.

Our cases emphasize the occurrence of hyperkinetic abnormal movements in DNA repair disorders. Subtle dystonia or tremor is often apparent in XP patients, even in those cases without overt neurological manifestations (PG observation). Recent reports have illustrated the relation between cerebellar atrophy and different movement disorders in mitochondrial conditions[23](#acn3511-bib-0023){ref-type="ref"} and HD.[24](#acn3511-bib-0024){ref-type="ref"} It is unclear whether the NER pathway could be particularly relevant for basal ganglia metabolism or whether the hyperkinetic movement disorders are a consequence of the cerebellar dysfunction: further studies are needed to elucidate the underlying pathogenesis.
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###### 

**Video S1.** *Segment 1*. Dystonic posture of the neck (with predominant laterocaput to the left and elevation of right shoulder) and the trunk was observed. The patient showed frequent blinking and choreic movements in the oromandibular area and the four limbs. In addition, lentigines in the face, the neck and hands are visible. *Segment 2*. The patient needed constant bilateral support of an accompanying person due to her imbalance. It is remarkable the broad‐based gait, with small steps and difficulty in turning, as well as the stoop position.

###### 

Click here for additional data file.
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